Functional Assessment of Geriatric Cancer Patients Needed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

NEW YORK-Despite considerable progress in the management and treatment of cancer in the overall population, cancer-related mortality among the elderly increased by 20% between 1970 and 1984. Cancer is often undertreated in the elderly, which affects their prognosis, said Roberto Bernabei, MD, of the Universita Cattolica del Sacro Cuore, Rome.

NEW YORK—Despite considerable progress in the management and treatment of cancer in the overall population, cancer-related mortality among the elderly increased by 20% between 1970 and 1984. Cancer is often undertreated in the elderly, which affects their prognosis, said Roberto Bernabei, MD, of the Universita Cattolica del Sacro Cuore, Rome.

Dr. Bernabei, who spoke at the Fifth International Conference on Geriatric Oncology, believes a new approach is needed to "deal with the ‘peculiarities’ of the elderly cancer patient." At his institution, Dr. Bernabei and his colleagues have developed and use a comprehensive geriatric assessment tool.

The new instrument, Minimum Data Set for Cancer (MDS-CA), documents the patient’s oncologic screening and treatment data, and provides a structured, multidimensional assessment of the patient’s general health, including cognitive and functional parameters, emotional and behavioral patterns, nutritional status, co-morbidities, lifestyle and preventive measures, quality of life, pain status, activity and movement status, continence status, informal support availability, and overall medications. "Such a tool," Dr. Bernabei said, "will provide an assessment that can help us build treatment decisions and monitor the treatment."

They have used this new instrument on 220 consecutive elderly patients referred to the oncologic consultation team after a new diagnosis of cancer. "We wanted to define the functional characteristics of these patients and understand who was treated with chemotherapy/radiotherapy and why," he said. Dr. Bernabei stressed that this approach already has shown "considerable benefits in different settings and for conditions other than cancer."

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content